- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04699032
Study of Pharmacokinetics and Safety of Apraglutide in Participants With Normal and Impaired Kidney Function.
A Phase 1, Open-Label Evaluation of the Pharmacokinetics and Safety of a Single Dose of Apraglutide in Subjects With Normal and Impaired Renal Function.
Study Overview
Detailed Description
A two stage design, open label, multi-center, non-randomized trial to evaluate the PK and safety of a single subcutaneous dose of 5 mg apraglutide in subjects with varying degrees of renal function. The renal function was calculated by the estimated glomerular filtration rate (eGFR) according to the Chronic Kidney Disease Epidemiology (CKD-EPI) Creatinine Equation.
Part 1: 8 subjects with severe renal impairment (Cohort 1) and 8 subjects with normal renal function (Cohort 2).
Part 2: 8 subjects with moderate (Cohort 3) and 8 subjects with mild (Cohort 4). Enrollment into Part 2 was conditional on the results of Part 1.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Florida
-
Orlando, Florida, United States, 32809
- Orlando Clinical Research Center
-
-
Minnesota
-
Saint Paul, Minnesota, United States, 55114
- Prism Clinical Research, Inc.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
All Participants
- Age between 18 and 75 years inclusive
- Subjects who are willing and able to comply with the study procedures
- Subjects able to understand and willing to sign the informed consent
- Body mass index (BMI) of ≥17.5 to ≤40 kg/m2; and a total body weight of >50 kg (110 lb).
- Women of childbearing potential (WOCBP) on highly effective method of contraception during the trial and for 1 month after the end of trial (EOT) visit. Sterilized or infertile or postmenopausal females.
- Male subjects with a female partner of childbearing potential: highly effective methods of contraception and no sperm donation during the trial and for 1 month after (EOT) visit.
Healthy participants
- No clinically relevant abnormalities (medical history, vital signs, ECG, safety labs)
- eGFR measured by CKD-EPI ≥90 mL/min/1.73 m2) at two screening visits
- Demographically comparable to the group of subjects with impaired renal function:
Participants with impaired renal function
- Severe renal impairment: eGFR <30 mL/min/1.73 m2, but not requiring hemodialysis
- Moderate renal impairment: eGFR ≥30 mL/min/1.73 m2 and <60 mL/min/1.73 m2
- Mild renal impairment: eGFR ≥60 and <90 mL/min/1.73 m2
Exclusion Criteria:
All Subjects
- Renal transplant recipients
- History of systemic infection
- Any active malignancies or history of malignancies within the past 2 years
- Acute or chronic medical or psychiatric condition
- Treatment with an IMP within 30 days or 5 half-lives (whichever is longer) preceding the dose of IMP
- Male subjects partners of WOCBP who are unable to comply with the contraceptive measures
- History of clinically significant intestinal adhesions and/or chronic abdominal pain
- History of known colon polyps or family history of familial adenomatous polyposis
- Positive blood screen for hepatitis C antibody, hepatitis B surface antigen or human immunodeficiency virus (HIV)-1 and -2 antibodies
- Serum albumin concentration <25 g/L (2.5 g/dL)
- Hemoglobin concentration <90 g/L (9.0 g/dL)
- Aspartate amino transaminase (AST) or alanine amino transaminase (ALT) values >2 × upper limit of normal (ULN)
- Proteinuria of >3 g total bilirubin >1.5 × ULN
- Positive urine test for alcohol or illicit drugs at either Screening or admission.
- Clinically significant abnormalities on 12-lead ECG
- Use of prescription or non-prescription drugs and dietary supplements within 7 days or five half-lives (whichever is longer) prior to Day 1. Stable concomitant medications may be given to subjects with renal impairment, if they are considered necessary for the welfare of the subjects.
- History of regular alcohol consumption exceeding seven drinks/week for females or 14 drinks/week for males (1 drink = 5 ounces [150 mL] of wine, or 12 ounces [360 mL] of beer, or 1.5 ounces [45 mL] of hard liquor) within 3 months of Screening
- Female subjects of childbearing potential who are unwilling or unable to use highly effective methods of contraception for the duration of the trial and for at least 1 month after the administration of the IMP; pregnant female subjects; female subjects planning to become pregnant during the duration of the trial and until 1 month after the administration of the IMP; breastfeeding female subjects
- Blood donation of approximately 500 mL or more within 60 days prior to the dose of IMP. Plasma donations of approximately 500 mL or more within 28 days prior to the dose of IMP
Additional Exclusion Criteria for Healthy Subjects with Normal Renal Function
- Evidence or history of clinically significant abnormalities
- Evidence or history of clinically significant dermatological condition
Additional Exclusion Criteria for Subjects with Impaired Renal Function
- Subjects requiring hemodialysis and/or peritoneal dialysis
- Subjects with other clinically significant disease
- Subjects with any significant hepatic, cardiac, or pulmonary disease or subjects who are clinically nephrotic. Hypertension, diabetes mellitus, hyperparathyroidism, ischemic heart disease are not cause for exclusion as long as the subject is medically stable and any drugs that are administered for these conditions are not expected to interfere with the PK of apraglutide.
- Screening BP ≥180 mmHg (systolic) or ≥110 mmHg (diastolic)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Severe Renal Impairment
eGFR (mL/min/1.73
m2): <30 not on hemodialysis
|
Single dose of apraglutide 5 mg.
|
Experimental: Normal Healthy Match
eGFR (mL/min/1.73 m2): ≥90
|
Single dose of apraglutide 5 mg.
|
Experimental: Moderate Renal Impairment
eGFR (mL/min/1.73
m2): ≥30 to 60
|
Single dose of apraglutide 5 mg.
|
Experimental: Mild Renal Impairment
eGFR (mL/min/1.73
m2): ≥60 to 90
|
Single dose of apraglutide 5 mg.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Plasma Concentration (Cmax) of Apraglutide
Time Frame: 5 minutes pre-dose up to 240 hours after dosing on Day 1
|
Pharmacokinetic (PK) samples collected for the measurement of plasma concentration of apraglutide were analyzed using a validated analytical method in compliance with applicable standard operating procedures.
|
5 minutes pre-dose up to 240 hours after dosing on Day 1
|
Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf) of Apraglutide
Time Frame: 5 minutes pre-dose up to 240 hours after dosing on Day 1
|
PK samples collected for the measurement of plasma concentration of apraglutide were analyzed using a validated analytical method in compliance with applicable standard operating procedures.
|
5 minutes pre-dose up to 240 hours after dosing on Day 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Time Frame: Day 1 up to Day 14
|
TEAEs were defined as adverse events (AEs) that occurred after dosing the participant with the study drug.
Participants with more than one TEAE were counted only once using the most severe event.
Vital signs, triplicate 12-lead electrocardiograms, or clinical laboratory assessments considered clinically significant by the Investigator were reported as AEs.
|
Day 1 up to Day 14
|
Number of TEAEs
Time Frame: Day 1 up to Day 14
|
The Investigator used the adjectives mild, moderate, or severe to describe the maximum intensity of the AE. These were defined as follows:
The Investigator systematically assessed the causal relationship of AEs to IMP/trial treatment using the definitions below:
A serious AE (SAE) was classified as any AE that:
|
Day 1 up to Day 14
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Gérard Greig, VectivBio AG
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TA799-014
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Kidney Disease
-
3-C Institute for Social DevelopmentUniversity of North Carolina, Chapel HillCompletedChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Pediatric Kidney Disease | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage V | Chronic Kidney Disease, Stage IV (Severe) | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease, Stage IUnited States
-
Universiti Putra MalaysiaRecruitingChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Requiring Chronic DialysisMalaysia
-
National Taiwan University HospitalCompletedChronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease Stage 1Taiwan
-
Centre Hospitalier le MansLe Mans UniversiteWithdrawnFatigue | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage3 | Chronic Kidney Failure | Chronic Kidney Disease, Stage 4 (Severe)
-
Centre Hospitalier le MansLe Mans UniversiteRecruitingFatigue | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease Stage 3BFrance
-
American Academy of Family PhysiciansUniversity of Colorado, Denver; National Institute of Diabetes and Digestive... and other collaboratorsCompletedChronic Kidney Disease | Chronic Renal Insufficiency | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney Insufficiency, ChronicUnited States
-
Lund UniversityBaxter Healthcare Corporation; Universidad de CórdobaCompletedEnd Stage Kidney Disease | Chronic Kidney Disease Requiring Chronic DialysisArgentina
-
Centre Hospitalier Saint Joseph Saint Luc de LyonNot yet recruitingKidney Failure, Chronic | Diet Habit | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage 3B | Chronic Kidney Disease, Stage 3 (Moderate) | Chronic Kidney Disease Stage 3A (Disorder)France
-
A.C. AbrahamsCompletedEnd Stage Renal Disease | Chronic Kidney Disease | End Stage Kidney Disease | Chronic Kidney FailureNetherlands
-
Far Eastern Memorial HospitalActive, not recruitingMetabolic Syndrome | Chronic Disease | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease Stage 3 | Chronic Kidney Disease Stage 4 | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease Stage 1Taiwan
Clinical Trials on Apraglutide
-
VectivBio AGCompletedShort Bowel SyndromeUnited States, France, United Kingdom, Israel, Korea, Republic of, Germany, Japan, Taiwan, Sweden, Belgium, Spain, Czechia, Hungary, Norway, Italy, Argentina, Denmark, Poland
-
VectivBio AGCompletedHealthy SubjectsNetherlands
-
VectivBio AGCompleted
-
VectivBio AGActive, not recruiting
-
VectivBio AGActive, not recruitingShort Bowel SyndromeUnited States, Belgium, United Kingdom, Korea, Republic of, Japan, Taiwan, Germany, France, Czechia, Hungary, Spain, Italy, Poland, Argentina, Denmark, Israel, Norway, Sweden
-
VectivBio AGCompletedShort Bowel SyndromeBelgium, France